Basic Information
| LncRNA/CircRNA Name | PANDAR |
| Synonyms | PANDAR, PANDA |
| Region | GRCh38_6:36673621-36675126 |
| Ensemble | ENSG00000281450 |
| Refseq | NR_109836 |
| Regulatory Mechanism | Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | oxaliplatin | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Information of Cancer
| Cancer Name | gastric cancer |
| ICD-0-3 | C16 |
| Methods | Microarray, qRT-PCR, RIP |
| Sample | GC tissues, normal gastric tissues, Gastric cancer cell lines (SNU-484, SNU-520, SNU-620, SNU-638, SNU-668, AGS, NCI-N87, SNU-1, SNU-5, KATO) |
| Expression Pattern | up-regulated |
| Function Description | Upregulated PANDAR in GC patients was positively correlated with increased tumour size, advanced TNM classification and a poor survival rate in GC patients. As a target, the CDKN1A gene was successfully downregulated by PANDAR. PANDAR controlled the transcription of the CDKN1A gene by competitively binding with p53 protein. In combination with a p53 activator (nutlin3), the knockout of PANDAR by CRISPR/Cas9 technology synergistically inhibited GC tumour growth in vivo.upregulated HOTAIR inhibits the expression of p53 by enhancing the p53 promoter histone H3 lysine 27 trimethylation (H3K27me3), and the overexpression of PANDAR increases the stability of the p53 protein in response to DNA damage. |
| Pubmed ID | 29416011 |
| Year | 2018 |
| Title | Long noncoding RNA PANDAR blocks CDKN1A gene transcription by competitive interaction with p53 protein in gastric cancer. |
External Links
| Links for PANDAR | GenBank HGNC Noncode |
| Links for gastric cancer | Omim Cosmic |